[{"id":"aa7593a1-12bf-4251-800d-895293ccfc91","acronym":"","url":"https://clinicaltrials.gov/study/NCT04555811","created_at":"2021-01-18T21:46:42.102Z","updated_at":"2024-07-02T16:35:54.835Z","phase":"Phase 1","brief_title":"FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL","source_id_and_acronym":"NCT04555811","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYC • BCL2 • BCL6","pipe":"","alterations":" ","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • FT596"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 02/08/2023","primary_completion_date":" 02/08/2023","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2023-02-23"}]